Form 4: Cytokinetics Director B. Lynne Parshall Equity Grant

Director B. Lynne Parshall acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.

Summary

• Director B. Lynne Parshall received an equity grant from Cytokinetics Inc. on May 27, 2026.
• The transaction included the acquisition of 2,851 shares of common stock at a price of $0.
• The director also received 4,301 non-qualified stock options with an exercise price of $77.15.
• Following these transactions, the director's total beneficial ownership of common stock is 20,784 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Standard market risks associated with equity holdings in a biotechnology company.

Future Outlook

The filing does not provide forward-looking guidance regarding company operations or financial performance.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practices in the biotechnology sector to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The grant of equity and options to board members is consistent with standard compensation packages for directors in mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new equity.

Next Steps

• Options become exercisable on June 27, 2026.

Key Dates

Keywords

Cytokinetics, CYTK, Form 4, Insider Trading, Equity Compensation, Director Ownership